Lyon Joseph Douglas sold $325K of CORT

Lyon Joseph Douglas (See Remarks) sold 5,000 shares of CORCEPT THERAPEUTICS INC (CORT) at $65.00 ($0.32M total) on 2026-05-27.

Original reporting
SEC EDGAR · Lyon Joseph Douglas
Published May 29, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 10:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with broader tape/valuation moves, but the filing alone does not change fundamentals.

02

Market read

Provides a discrete insider selling datapoint that can slightly influence sentiment, with limited direct trading edge absent additional fundamental catalysts.

03

What to watch

The transaction is explicitly noted as not under a pre-arranged 10b5-1 plan, which can increase perceived signal—but the article lacks context on prior holdings, sale frequency, or tax/portfolio constraints.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed May 29 (covering sale on May 27)

Background

The article is an SEC insider transaction disclosure (Form 4) for Corcept Therapeutics, reporting an officer’s open-market sale.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics officer Lyon Joseph Douglas sold 5,000 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Low, likely limited to short-term sentiment/flow effects rather than a sustained repricing.

Evidence & confidence

The filing provides a single insider sale datapoint (value ~$325k) without any accompanying operational or guidance change; impact is typically modest unless part of a broader pattern.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide signal.

None indicated.

None indicated.

Counterpoint

A one-off insider sale may reflect diversification or liquidity needs and may not signal reduced confidence, especially without a larger sequence of sales.

Key entities

  • Corcept Therapeutics Inc

    Subject of the SEC Form 4 insider sale disclosure.

  • Lyon Joseph Douglas

    Officer who sold 5,000 shares of CORT on May 27, filed May 29.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.